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ABSTRACT:  
There is a renewed interest in better conceptualizing trajectories of Attention-
Deficit/Hyperactivity Disorder (ADHD) from childhood to adulthood, driven by an 
increased recognition of long-term impairment and potential persistence beyond 
childhood and adolescence. This review addresses the following major issues 
relevant to the course of ADHD in light of current evidence from longitudinal 
studies: 1) conceptual and methodological issues related to measurement of 
persistence of ADHD; 2) estimates of persistence rate from childhood to 
adulthood and its predictors; 3) long-term negative outcomes of childhood 
ADHD and their early predictors, and 4) the recently proposed new adult-onset 
ADHD. Estimates of persistence vary widely in the literature, and diagnostic 
criteria, sample characteristics and information source are the most important 
factors explaining variability among studies. Evidence indicates that ADHD 
severity, comorbid conduct disorder and major depressive disorder, and 
treatment for ADHD are the main predictors of ADHD persistence from 
childhood to adulthood.  Comorbid conduct disorder and ADHD severity in 
childhood are the most important predictors of adverse outcomes in adulthood 
among children with ADHD. Three recent population studies suggested the 
existence of a significant proportion of individuals who report onset of ADHD 
symptoms and impairments after childhood. Finally, we highlight areas for 
improvement to increase our understanding of ADHD across the life span. 
 
KEYWORDS: ADHD; persistence; outcomes; predictors; course; longitudinal 
investigations
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INTRODUCTION 
Attention-Deficit/Hyperactivity Disorder (ADHD) is a neurobiological disorder 
characterized by a persistent and impairing pattern of inattentive, hyperactive, 
and/or impulsive symptoms [1]. Meta-analyses suggest prevalence rates around 
5 to 7.1% in childhood and 2.5 to 5% in adulthood [2-4]. The disorder is 
associated with adverse outcomes for affected individuals, their families and 
society in general [5]. 
There is recent interest in better conceptualized adult ADHD [6] and its 
trajectories from childhood to adulthood [5]. A previous meta-analysis found that 
only 15% of diagnosed children continued presenting full ADHD diagnosis in 
adulthood, although 65% presented with a subsyndromal phenotype [7]. This 
figure would suggest a much lower adult ADHD prevalence rate (15% of 5-7% = 
0.8-1.1%) than what has been detected both in meta-analyses (2.5%-5%) [3, 4] 
and in a multi-national study on ADHD prevalence in adults (3.4%) [8]. There is 
a current debate about reasons for this discrepancy. Some investigators 
suggest that the 15% persistence rate is a clear underestimation due to change 
of informants between adult and child assessments and inadequacy of the 
ADHD diagnostic criteria for adults. Major aspects of both the ADHD phenotype 
and its impairments might be different in adults, and other approaches to define 
persistence, like cognitive and social dysfunction, are lacking in the literature.[6] 
In addition, controversies also exist surrounding new findings suggesting an 
unexpected ADHD trajectory. Three recent population studies found a 
substantial number of individuals with onset of clinically significant ADHD 
symptoms and impairments after childhood, challenging the established notion 
of ADHD as exclusively a childhood-onset neurodevelopmental disorder. [9-11] 
This narrative review of the literature addresses the following topics that might 
increase our understanding about these discrepant findings: a) conceptual and 
methodological issues inherent to the study of ADHD trajectories; b) data on 
persistence rates from longitudinal ADHD studies; c) predictors of ADHD 
persistence from childhood to adulthood; d) child and adolescent predictors of 
adult ADHD negative outcome; e) new adult-onset cases and their predictors.  
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CONCEPTUAL AND METHODOLOGICAL ISSUES INHERENT TO THE 
STUDY OF ADHD TRAJECTORIES 
a) ADHD Diagnosis 
In the last 50 years, the diagnostic criteria for ADHD from DSM-II to DSM-5 
have been modified [1, 12, 13]. Previous work has demonstrated that use of 
different diagnostic criteria is one of the major factors influencing variability in 
ADHD prevalence rates worldwide over the last three decades [2, 14]. ADHD 
persistence is the proportion affected by the diagnostic definitions in childhood 
(denominator) who also meet the definition in  adult life (numerator) [6,9]. A birth 
cohort study with assessments of the disorder from childhood to adulthood (15) 
provided different ADHD persistence rates depending on the diagnostic system 
used on multiple follow-up waves [15]. An adult norm-based diagnostic 
approach yielded the highest persistence rate compared to any other 
approaches (29.3% against 11.2% to 13.8% for strict criteria definitions). While 
some studies assessed individuals at baseline in childhood for ADHD using 
previous classifications (DSM-II, DSM-III) [16-21], others used more 
contemporary systems such as DSM-IV [11, 22, 23]. Assessments at follow up 
are likewise a source of heterogeneity in persistence estimates: studies have 
used DSM-III [17, 24], DSM-IV [15, 20, 21, 25], and DSM-5 [9, 11] criteria to 
determine ADHD diagnosis in adulthood. Differences of criteria may occur even 
in a same study in longitudinal assessments.  
 
One study evaluated how differences in case definition might impact 
persistence estimates in the 16-year clinical follow-up of the Multimodal 
Treatment Study of ADHD (MTA) [26]. Persistence estimates varied widely from 
1.9% (requiring DSM-IV criteria, combining parent and self-report in the 
Diagnostic Interview Schedule for Children (DISC) with an item-level AND rule) 
to 61.4% (requiring norm-based symptom count, combining parent and self-
report in the DISC with an item-level OR rule). Based on findings from a ROC 
analysis of impairment, the authors concluded that the best combination of 
sensitivity and specificity was achieved using a norm-based threshold of four 
symptoms from either list (more than two standard deviations above the mean 
of the local normative comparison group) assessed with rating scales and 
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combining parental and self-report information with an item-level OR rule. This 
approach yielded a persistence rate of 60% for symptoms and 41% for 
symptoms with impairment.  
 
Although the presence of impairment has been required by the successive 
revisions of diagnostic criteria for ADHD, the level of impairment required is not 
unanimous. The level of impairment substantially affects variability in ADHD 
prevalence rates worldwide and across the last three decades [2, 14]. Using full 
DSM-5 criteria, a recent population study assessing ADHD prevalence in adults 
[27] found a rate of 3.55% (95%CI 2.98–4.12%) for at least moderate 
impairment, but only 1.4% for severe clinical impairment. Thus, diagnostic rates 
vary substantially from one study to another depending on the level of 
impairment required for diagnosing the disorder at baseline and endpoint, [28].  
 
Another conceptual issue is the source of impairment, which has varied 
across studies. Some studies used general measures of impairment, such as 
the Clinical Global Assessment Scale [29], Clinical Global Impression Scale 
[30], or the Global Assessment of Functioning [31], while others used measures 
that specifically assess impairment derived from ADHD symptoms, such as 
questions included in ADHD modules of structured or semi-structured 
diagnostic instruments [11, 20, 21]. Instruments created to assess impairment 
specifically related to ADHD, as the Barkley Functional Impairment Scale (BFIS) 
were also used [22]. Two paramount clinical follow-ups, the multimodal 
treatment Study of children with ADHD (MTA) [26] and the Pittsburgh ADHD 
Longitudinal Study (PALS) [32], used the Impairment Rating Scale (IRS) 
proposed by Fabiano et al for children with ADHD. [33] Although it is 
questionable whether the source of impairment can be clearly specified when 
comorbidity is the rule, persistence rates ascertained by different instruments, 
even for the same level of impairment, may be substantially different. 
              
b) Sample characteristics 
The origin of the sample (community or clinical) affects prevalence rates and 
clinical correlates of psychiatric disorders [34]. Clinical samples of individuals 
with ADHD in general include more severe cases than population samples and 
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thus, report increased comorbidity [35]. Part of this increased morbidity is 
expected according to the “Berkson’s Bias”, a mathematical bias due to 
restricting the sample to those individuals seeking clinical treatment and 
showing greater levels of severity and comorbidity [34, 36]. Thus, it is not 
surprising that ADHD persistence rates appear to be higher in clinical samples 
[18, 22, 23, 28] than in population-based samples [9-11]. Barriers to health 
services across countries also affect persistence rates. It is expected that 
clinical samples will select more severe and socially deprived cases in countries 
with accessible health care like the UK or Scandinavian countries. [37] 
 
Additionally, retention rate is related to selection bias [38] affecting the 
representativeness of the sample, especially in population-based samples.  A 
population-based sample with a substantial amount of participants lost to follow-
up might underestimate persistence rates, since severe cases may have a 
higher risk of persistence and a higher risk of not attending several longitudinal 
assessments. [39].  
         
c) Demographic aspects 
Longitudinal ADHD studies assess individuals at different ages both at 
baseline in childhood and end point during adulthood [11, 40]. Considering the 
general trend that prevalence rates of ADHD decrease across the life cycle, 
regardless of the criteria used (see Faraone, Biederman, and Mick, [7]), age at 
assessment might be another factor influencing persistence rates. The literature 
shows that ADHD prevalence in adolescence is about half of that in childhood 
[2], and prevalence estimates continue to decrease in adulthood. This has been 
illustrated most clearly by a long ADHD follow-up study that assessed 
participants with childhood-onset ADHD at different time points in adulthood. 
The prevalence of ADHD declined to 43% at 18 years of age and 22% at 41 
years (Mannuzza et al. [17]; Klein et al. [41]). In addition to attrition, these 
studies used different informants and diagnostic criteria classifications at 
different assessment points in adulthood, making it unclear whether the 
decrease in rate was mainly due to age or methodology. Regardless, age at 
entry into the study and age at endpoint clearly affect reported persistence 
rates. 
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The literature in general also suggests that females might have a higher 
persistence rate than males, as well as more negative outcomes in adulthood 
[42], although this could not be confirmed in the MTA sample. This sex 
difference might be responsible in part for the lower, in some studies absent, 
male/female preponderance during adulthood (see Matte et al. [27]; Vitola et al., 
personal communication). Thus, the proportion of females in the study may 
affect the observed persistence rate. This might be even more important in 
studies reporting persistence rates based on samples composed exclusively of 
males or females [17, 20, 21]. However, these differences might also be due to 
higher severity, comorbidity or adverse social background of girls diagnosed 
with ADHD compared to boys, instead of being only determined by gender.  
 
d) Informants  
Who is reporting the information is a major factor explaining heterogeneity in 
worldwide ADHD prevalence in childhood and adolescence [2]. The agreement 
between parents and teachers on ADHD symptoms is low in childhood, and the 
literature indicates that children tend to underreport their ADHD symptoms [5]. 
Consequently, the choice of the informant in childhood impacts the estimate of 
prevalence, and changing sources may impact estimates of persistence. As a 
complication, this informant effect may differentially influence various aspects of 
ADHD diagnostic criteria (e.g., either symptoms or impairment).  
Although some reports suggest good inter-rater reliability between adult self-
report and parent reports of childhood and adulthood symptoms [43], others 
documented that neither are reliable for retrospectively reporting ADHD 
symptoms in childhood [9, 44]. In adult clinical studies, parents or relatives that 
knew the individual during childhood tend to report retrospectively fewer 
childhood ADHD symptoms than adult retrospective self-reports [32, 45], the 
opposite of adult current report on symptoms and impairments [26, 42].  
Thus, persistence rates will depend heavily on which information source was 
selected during childhood and adulthood. This is especially important because 
some studies change information source from the parent source in childhood to 
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affected individual (self) source in adulthood, potentially artificially deflating 
persistence rates [9-11]. 
 
DATA ON PERSISTENCE RATES FROM LONGITUDINAL ADHD STUDIES 
FROM CHILDHOOD TO ADULTHOOD 
Based on the issues discussed above, it is not surprising that ADHD 
persistence rates from childhood to adulthood vary substantially among studies 
(Figure 1). The figure shows estimates of full ADHD diagnostic persistence 
reported by longitudinal studies that followed children to a mean age of at least 
18 years. A comparison of the extremes is informative. The lowest rate detected 
was 4% in a clinical study in the US [17]. This study followed referred boys 
diagnosed with DSM-II hyperkinetic disorder at ages 5 to 11 years and 
reassessed their ADHD status 17 years later with DSM-III-R criteria. Potential 
factors responsible for this low rate include: 1) The sample was composed 
exclusively of males (see below); 2) Patients with comorbid conduct disorder at 
baseline were excluded; 3) Change of diagnostic system and assessment 
approach: DSM-II with clinical interview at baseline and DSM-III-R with 
structured interview at follow up; 4) Requirement of endorsement of childhood 
ADHD symptoms and impairment at follow up to diagnose adult ADHD; 5) The 
strict use of a DSM threshold instead of a norm-based approach. The authors 
emphasize that recall bias might have constrained the persistence rate (see 
Klein et al. [41]). The highest ADHD persistence rate found was 76% in the UK 
study by Cheung and colleagues [22]. Authors followed children and 
adolescents (mean age 11.8, 87% males) with ADHD combined type (DSM-IV) 
criteria for 6.6 years. Factors that might be responsible for this very high rate 
include: 1) A short follow-up time; 2) Similarity of assessment in the two time 
points, using DSM-IV and a structured interview and no change of information 
source (parent report); 3) A clinical sample composed of only ADHD combined 
type (see below); 4) relatively young age at follow up .  
 
PREDICTORS OF ADHD PERSISTENCE FROM CHILDHOOD TO 
ADULTHOOD 
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The comprehensive review of persistence rates found few studies that report 
factors in childhood related to the course of symptoms into adulthood. A recent 
systematic review and meta-analysis summarizing the findings thus far 
concluded that available reports are heterogeneous and hard to combine [46]. 
However, a meta-analysis of predictors assessed and reported by at least three 
studies is summarized in Table 1. 
Characteristics of the clinical syndrome were the most consistent risk factor for 
persistence: comorbid conditions like Conduct Disorder (CD) and Major 
Depressive Disorder (MDD), severe ADHD, and treatment for ADHD are 
associated with ADHD persistence. The finding that ADHD treatment is a risk 
factor for persistence is not surprising, since the most severe cases are 
selected for treatment. Barriers to health care may influence this finding; lack of 
access to treatment might be a marker of environmental or socioeconomic risk 
factors (e.g, ethnic minorities or living in an area with limited resources [47, 48]. 
Importantly the two studies that found the effect of ADHD treatment adjusted 
their findings for disorder severity, but possibly the treatment-severity 
relationship was not fully captured by the instruments used. A clinical study that 
followed individuals for 5 years after a 12-month randomized clinical trial found 
that medication adherence was related to greater improvement but higher end-
point symptoms, while symptom severity at baseline was the most important 
single predictor of persistent symptoms at follow-up [49]. Disentangling this bias 
adequately would require a randomized clinical trial with good adherence and 
retention for several years comparing outcome between allocated groups at 
baseline. However, maintaining adherence to assigned treatment over long 
periods may not be possible. 
An analysis of the MTA evaluated childhood factors influencing persistence of 
ADHD into adulthood at a mean age of 24.7 years [50]. ADHD symptom 
severity, comorbidities, and parental mental health problems were the most 
important risk factors for persistence, while childhood IQ, socioeconomic status, 
parental education and parent-child relationships showed no association with 
persistence. These findings are, in general, similar to what was reported in the 
meta-analysis (see Table 1). However, treatment assignment was not evaluated 
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as a risk factor, having been found in previous reports to have lost significant 
association with symptom severity by 3 years [51, 52].  
 
EVALUATION AND PREDICTION OF TRAJECTORIES OF ADHD 
SYMPTOMS 
Another possible approach to evaluate persistence and remission is to 
investigate trajectories of symptoms rather than categorical diagnosis. Since 
few studies using this approach followed subjects from childhood to adulthood, 
we also included studies where the last assessment was in late adolescence in 
this section.  
One study evaluated baseline differences between trajectories of ADHD 
symptoms (persistently high compared to declining) through grades 3 to 12, 
when participants are expected to be 17 or 18 years old [53]. Participants with a 
more chronic trajectory were more aggressive and more hyperactive at school, 
and more emotionally dysregulated at home than their peers with a declining 
trajectory of ADHD symptoms. The investigators also reported a more stable 
pattern of inattentive symptoms compared to hyperactive symptoms, a finding 
that was reported in previous studies [54].  In a different study, 8395 twin pairs 
were assessed for ADHD at ages 8, 12, 14 and 16 with a DSM-IV ADHD 
symptom subscale. [55] Consistent with population-based and clinical studies, 
there was a general decline of symptoms across ages, and inattentive 
symptoms persisted more than hyperactive/impulsive symptoms. Authors 
reported important inter-individual differences in the developmental course of 
symptoms, mostly explained by genetic influences independently of baseline 
severity. Another study (Howard et al, 2016) showed protective effects related 
to parenting and attendance in college that were manifested in the transition 
from adolescence to adulthood [56]. In the adult assessment of the MTA, a 
dimensional outcome based on symptom-severity showed a large difference 
between the overall ADHD group and comparison group. However, neither 
initial random allocation to treatment with medication nor self-selected, 
extended use of medication significantly predicted adult outcomes on this 
variable within the ADHD group (Swanson et al., personal communication).  
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The Avon Longitudinal Study of Parents and Children, a large birth cohort in the 
UK, analyzed factors associated with latent-class trajectories of ADHD 
symptoms  age 4 to 17 years. The persistent class (3.9% of the sample and 
40.2% of participants with high childhood scores ) had mostly males (72.9%) 
and higher conduct problems, language impairments, and social-communication 
problems and lower IQs. Also, the persistent group had higher ADHD genetic 
liability as indexed by ADHD polygenic risk scores, whereas other psychiatric 
genetic risk scores (schizophrenia, bipolar disorder and depression) were not 
associated with trajectories (Riglin et al, personal communication). 
  
PREDICTORS OF ADULT ADHD DELETERIOUS OUTCOMES THAT CAN 
BE DETECTED IN CHILDHOOD AND ADOLESCENCE 
There is substantial evidence documenting adverse outcomes for those affected 
by ADHD compared to those without the disorder [5, 6]. ADHD affects a wide 
range of functional domains including academic, social, and occupational 
contexts. Studies have documented lower academic achievement [57, 58], 
higher unemployment, and lower income for probands with ADHD followed into 
adulthood [28, 59, 60]. The risk of substance use disorders (SUD) and 
antisocial personality disorder is higher in patients with ADHD than in non-
affected individuals [61-65]. Individuals with ADHD are more likely to have traffic 
accidents than the general population [66-68]. Other documented outcomes 
include obesity [69, 70], dysfunctional family relationships [28, 71] and 
emotional dysregulation [72]. These functional impairments may result in 
reduced perception of well-being [73] and be related to adverse outcomes like 
higher overall mortality rates in individuals with current or past ADHD diagnosis 
[74]. A comprehensive meta-analysis has confirmed a longitudinal association 
of childhood ADHD with adverse outcomes, the most relevant being mental 
disorders and substance abuse, academic and professional underachievement, 
criminality, and risky driving behaviors [75]. The 16-year follow-up of the MTA 
showed that adverse outcomes in education, work, and risky sexual behavior 
were associated with ADHD and symptom persistence; the risk increases in a 
progressive fashion: the local normative comparison group (LNCG) had the 
lowest risk, symptom-persistent ADHD the highest, with symptom-desistent 
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ADHD in between. For emotional outcomes, like anxiety and depression, there 
difference was not significant between those whose symptoms remitted and the 
LNCG, while both were doing better than ADHD persisters. Alcohol use and jail 
time did not differ significantly across any of the groups assessed, probably 
because alcohol use was so common and jail time so rare [76].  
Although these adverse adult outcomes associated with ADHD are 
unquestionable, much less clear are their childhood predictors. Several factors 
have been suggested as influencing the outcome in ADHD subjects, like the 
clinical profile (ADHD severity and comorbidities), pre-natal factors [77], genetic 
and family loading, gene-environment interactions, and protective factors like 
exercise and cognitive ability [5, 78].  
A recent systematic review and meta-analysis on ADHD and criminality 
consistently identified these risk factors for arrests, convictions and 
incarcerations [79]: male sex, low intelligence quotient, severe ADHD, and 
comorbid conduct disorder. Low socioeconomic status was associated in 
univariate analysis but the effect faded in multivariate analysis. A study of 
unimodal (medication only) and multimodal treatments initiated in the 1970s 
evaluated long-term effects and showed an initial protective effect in the 
multimodal treatment group that dissipated in the adult follow up [80, 81]. 
ADHD severity, comorbid conduct disorder and oppositional defiant disorder, 
sexual abuse, school suspension, family history of SUD or ADHD and male 
gender were associated with SUD development in ADHD, whereas ADHD 
inattentive subtype and a fearful temperament were inversely associated [82]. 
One study found that the development of SUD in adulthood was predicted by 
age of treatment initiation in childhood (the later, the higher the risk for SUD) 
and that the relation was moderated by antisocial personality disorder [83]. The 
MTA found no residual effect of initial assignment to 14 months’ treatment with 
medication  and no effect of current treatment with medication in the 
development of SUD in adolescence [84]. The PALS, a clinical follow-up, found 
medication to be a risk factor that lost significance when controlling for other 
factors at baseline [85]. 
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A cross-sectional analysis of data from nationwide registers found the overall 
mortality rate higher among ADHD patients than in the general population, and 
the risk was especially higher in females, and with comorbid oppositional defiant 
disorder, conduct disorder, and SUD. The mortality rate ratio was 4.25 (95% 
confidence interval: 3.05-5.78) for individuals diagnosed with ADHD at ages 18 
or older, compared to 1.86 for 5 or younger and 1.58 for those diagnosed 
between 6 and 17 years of age [74]. 
In the Milkauwee follow-up study, higher ADHD scores in childhood predicted a 
wide range of worse outcomes like educational, occupational, financial and 
driving problems, whereas lower IQ was associated only with worse educational 
and occupational outcomes [28]. 
NEW ADULT-ONSET CASES AND THEIR PREDICTORS 
Historically, ADHD has been conceptualized as a child-onset 
neurodevelopmental disorder [86]. The last DSM version (DSM-5) launched in 
2013 [1] included the disorder in the neurodevelopmental disorders section. 
Three recent population studies from diverse cultures challenged the notion that 
ADHD has its onset only in childhood by suggesting the existence of a 
significant large proportion of individuals who report onset of ADHD symptoms 
and impairments after childhood [9-11]. The most surprising finding among the 
three studies is the similarity in the rates of these new adult-onset cases in the 
three studies: 87% of the adults with ADHD presented new adult-onset in the 
New-Zealand study [9], 87.4% in the Brazilian study [10], and 67.5% in the UK 
investigation [11]. However, issues have been raised about the meaning of 
these findings. One hypothesis is that the new onset cases are the result of the 
false positive paradox. Another explanation is that in all three samples there 
was a shift from parent-report or teacher report in childhood to self-report in 
adulthood. However, the British study has controlled for this potential bias in 
secondary analyses[11]. A recent analysis in the ALSPAC cohort relying on the 
same source information for assessments, and using a screening instrument for 
ADHD (hyperactive SDQ scale) at ages 7 and 17 years old (parental 
assessment), found that 54% of the adult cases were new-onset cases. In 
addition, the persistence rate was only 22%. (Riglin et al, personal 
communication).  
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In an analysis of predictors in childhood for the adult-onset ADHD cases, the 
British study [11] found that higher IQ, and lower externalizing and internalizing 
scores differentiated the adult-onset individuals from the ADHD persistent 
group. One possible explanation for this would be that high intelligence and lack 
of comorbidity allow the disorder to go undetected during childhood and 
adolescence.  In the Dunedin study, the following childhood factors differentiate 
the adult ADHD group from non-ADHD adult group: higher ADHD scores by 
teachers’ report, conduct disorder and lower reading ability scores [9]. Future 
investigations need to clarify which factors predict adult-onset cases compared 
to individuals without ADHD. An international effort comparing data sets from 
different cultures on this question is ongoing. 
  
CONCLUSIONS 
Several methodological factors intrinsically related to the ADHD diagnosis (e.g., 
diagnostic criteria), demographic and sample characteristics (e.g., clinical or 
population origin and age), and information source (self or other) seem to be 
responsible for different persistence rates from childhood to adulthood among 
studies. Since evidence from longitudinal studies on ADHD is scarce and 
extremely heterogeneous in methodology, it is difficult to disentangle with 
statistical methods the role of each of these factors in explaining the 
heterogeneity of ADHD persistence rate. This scenario results in a wide range 
of observed persistence rates among studies, from as low as 4% [17] to as high 
as 76% [22]. 
The available literature indicates that ADHD severity, comorbid conduct 
disorder and major depressive disorder and treatment for ADHD are the main 
predictors of ADHD persistence from childhood to adulthood [46]. Comorbid 
conduct disorder in childhood is ubiquitous as a predictor of multiple adverse 
outcomes like premature mortality, SUD, and criminality, whereas other factors 
have controversial effects depending on the study. Male sex is a risk factor for 
SUD and criminality but is protective in terms of the overall mortality rate. 
Stimulant medication use may protect against the development of SUD 
(although the MTA, the largest prospective study, failed to find such an effect). 
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Severity of ADHD appears to be positively associated with criminality and SUD, 
but its relationship with mortality could not be assessed due to lack of data.  
Finally, innovative investigations like those suggesting the possibility of an 
adult-onset ADHD trajectory predicted by higher cognitive reserve and lower 
symptomatology in childhood are important to expand our knowledge about 
ADHD trajectories across the life cycle.      
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Figure 1. Estimates of ADHD persistence rates into adulthood in longitudinal studies. 
 
All reported studies are longitudinal studies with mean age at follow up of at least 18 years old and a 
full diagnosis (syndromatic) definition of persistence. 
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Table 1. Summary of risk factors reported in the systematic review and meta-analysis by Caye 
and colleagues (2016). 
Factors meta-analyzed and significantly associated with persistence 
PREDICTOR ODDS RATIO 95% CONFIDENCE 
INTERVAL 
P-VALUE 
 
Severe ADHD 
 
2.33 
 
1.6 – 3.39 
 
< 0.001 
 
Treatment for ADHD 
 
2.09 
 
1.04 – 4.18 
 
0.037 
 
Comorbid Major Depressive Disorder 
 
1.80 
 
1.1 – 2.95 
 
0.019 
 
Comorbid Conduct Disorder 
 
1.85 
 
1.06 – 3.24 
 
0.03 
Factors meta-analyzed nonsignificantly associated with persistencea 
PREDICTOR ODDS RATIO 95% CONFIDENCE 
INTERVAL 
P-VALUE 
 
Female gender 1.23 0.84 – 1.81 0.295 
Comorbid ODD 1.65 0.75 – 3.65 0.213 
Factors meta-analyzed and consistently not associated with persistence 
PREDICTOR ODDS RATIO 95% CONFIDENCE 
INTERVAL 
P-VALUE 
Single parent family 1.08 0.25 – 1.29 0.179 
PREDICTOR SMDb 95% CONFIDENCE 
INTERVAL 
P-VALUE 
Intelligence quotient 0.03 -0.18 - -0.23 0.8 
Factors not meta-analyzed but associated with persistence in individual studies 
Combined ADHD Subtype • Comorbid Bipolar Disorder • Parental ASPDc 
 
a. Authors note that sensitive analysis or the adoption of less conservative meta-analysis techniques (fixed-
effects models) would result in a positive and significant association for Comorbid ODD and female gender, 
whereas single parent family and intelligence quotient have consistent small and not significant effects on 
persistence across included studies.  
b. Standardized Mean Difference 
c. Antisocial Personality Disorder 
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REFERENCES OF IMPORTANCE 
Reference How it adds to the literature 
             REFERENCES OF MAJOR IMPORTANCE 
● ● Hechtman et al (2016) A report on long-term outcomes of ADHD children and controls 
within the larger clinical trial on the field and its relationship with 
symptom persistence and desistance. 
● ● Caye et al (2016) First systematic review of childhood predictors of ADHD 
persistence. Provides summarized estimates of risk with meta-
analytic techniques. 
● ● Moffitt et al (2015) The first time that the late-onset ADHD was reported in an 
analysis of a four-decade longitudinal cohort. 
● ● Dalsgaard et al (2015) An analysis of health records found a significant association 
between ADHD and overall mortality.  
● ● Erskine et al (2016) A comprehensive systematic review of long-term outcomes of 
ADHD and conduct disorder. Provides summarized estimates of 
risk with meta-analytic techniques. 
             REFERENCES OF IMPORTANCE 
● Sibley et al (2016) This was the first study to analyze a wide range of ADHD 
persistence definitions and test for the accuracy of those 
definitions within one clinical sample. 
● Agnew-Blais et al (2016) An UK longitudinal cohort found similar results in regard to the 
late-onset ADHD and reported factors from childhood related to 
this trajectory.  
● Caye et al (2016) A Brazilian longitudinal cohort found similar results in regard to 
the late-onset ADHD and tested for multiple confounding factors 
in secondary analyses. 
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